Literature DB >> 11683683

Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine.

O H Nielsen1, B Vainer, J Rask-Madsen.   

Abstract

The thioguanine derivative, azathioprine, is a prodrug of 6-mercaptopurine that is further metabolized by various enzymes present in the liver and gut. Azathioprine and 6-mercaptopurine have been used in the treatment of inflammatory bowel disease, i.e. ulcerative colitis and Crohn's disease, for more than 30 years. However, widespread use of azathioprine or 6-mercaptopurine in inflammatory bowel disease is of more recent origin, the primary reason being a long-standing debate on the efficacy of these agents in inflammatory bowel disease. Both drugs are slow acting, which is why clinical efficacy cannot be expected until several weeks or even months of treatment have elapsed. Consequently, azathioprine and 6-mercaptopurine have no place as monotherapy in the treatment of acute relapsing inflammatory bowel disease. Today, azathioprine and 6-mercaptopurine are the most commonly used immunomodulatory drugs in the treatment of inflammatory bowel disease. Their clinical effects are probably identical, although their exact mode of action is still unknown. The mode of action of azathioprine is thought to be multifactorial, including conversion to 6-mercaptopurine (which acts as a purine antimetabolite), possible blockade of thiol groups by alkylation, inhibition of several pathways in nucleic acid biosynthesis (preventing proliferation of cells involved in the determination and amplification of the immune response) and damage to DNA through the incorporation of thiopurine analogues. However, 6-thioguanine nucleotides may accumulate in toxic doses in myeloid precursor cells, resulting in life-threatening myelosuppression. Azathioprine and 6-mercaptopurine are further known to alter lymphocyte function, reduce the number of lamina propria plasma cells and affect natural killer cell function. The purpose of this comprehensive review is to suggest guidelines for the application of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683683     DOI: 10.1046/j.1365-2036.2001.01102.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  31 in total

1.  Expression of thiopurine methyltransferase in South Asians.

Authors:  E Tsironi; M Browne; D S Rampton; A B Ballinger
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

Review 2.  Medical approaches and future options in chronic active ulcerative colitis.

Authors:  J T Siveke; C Folwaczny
Journal:  Int J Colorectal Dis       Date:  2004-01-15       Impact factor: 2.571

3.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  M J Carter; A J Lobo; S P L Travis
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

4.  Colitic cancer developed after introduction of azathioprine.

Authors:  Jun-ichi Sasaki; Yutaka J Kawamura; Fumio Konishi; Tsutomu Tosha
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

Review 5.  Immunosuppression: towards a logical approach in liver transplantation.

Authors:  I Perry; J Neuberger
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

6.  Outcome of patients with nonstenotic, nonfistulizing Crohn's disease.

Authors:  Pilar Nos; Vicente Garrigues; Guillermo Bastida; Nuria Maroto; Marta Ponce; Julio Ponce
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

7.  FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression.

Authors:  Alf Lamprecht; Hiromitsu Yamamoto; Nathalie Ubrich; Hirofumi Takeuchi; Philippe Maincent; Yoshiaki Kawashima
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

Review 8.  Perianal Crohn's disease: is there something new?

Authors:  Cesare Ruffolo; Marilisa Citton; Marco Scarpa; Imerio Angriman; Marco Massani; Ezio Caratozzolo; Nicolò Bassi
Journal:  World J Gastroenterol       Date:  2011-04-21       Impact factor: 5.742

9.  Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease.

Authors:  Ferenc Nagy; Tamas Molnar; Zoltan Szepes; Klaudia Farkas; Tibor Nyari; Janos Lonovics
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

10.  An ab initio and AIM investigation into the hydration of 2-thioxanthine.

Authors:  Xiu-Xiang Yuan; Yan-Fang Wang; Xin Wang; Wenbo Chen; John S Fossey; Ning-Bew Wong
Journal:  Chem Cent J       Date:  2010-03-23       Impact factor: 4.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.